Core Viewpoint - The company is utilizing its own funds to pay for investment projects and will subsequently replace these funds with raised capital, ensuring efficient use of funds and smooth project implementation [1][6][7] Fundraising Overview - The company issued 16,229,100 shares at a par value of 1.00 RMB per share, raising a total of approximately 1.31 billion RMB after deducting issuance costs [1][2] - The total expected investment for the projects funded by the raised capital is approximately 434.36 million RMB [2][3] Investment Project Details - The company has established a dedicated account for the raised funds, which are fully stored in this account and are subject to a tripartite/four-party supervision agreement with the sponsor and the bank [2] - The net amount raised from the initial public offering is 1,308,998,865.06 RMB, with excess funds available for investment [3] Reasons for Using Own Funds - The company’s U.S. subsidiary, Bepharm Scientific Inc, initially paid for automation equipment costing 1.5 million USD due to delays in foreign investment filing [4][5] - Payments for salaries, bonuses, and other operational costs must be made from the company's basic deposit account, not from the raised funds account, to comply with banking regulations [4] - Frequent small payments for project-related expenses would complicate fund management if made directly from the raised funds account, thus necessitating the use of own funds initially [5] Operational Process for Fund Replacement - The company will submit payment requests for project-related expenses, initially using its own funds, and will replace these with raised funds within six months following the payment [6] - A detailed record will be maintained to ensure compliance with the investment project requirements [6] Impact on Daily Operations - The use of own funds followed by replacement with raised funds is expected to enhance the efficiency of fund utilization and project implementation without affecting the normal operation of investment projects [6][7] Review Procedures - The board of directors has approved the use of own funds for project expenses, ensuring compliance with relevant regulations and confirming that this does not alter the intended use of raised funds [6][7]
毕得医药: 国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司使用自有资金支付募投项目所需资金并以募集资金等额置换的核查意见